GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Chase Sun Pharmaceutical Co Ltd (SZSE:300026) » Definitions » Beneish M-Score

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Beneish M-Score : -2.68 (As of Apr. 16, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Tianjin Chase Sun Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.68 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Tianjin Chase Sun Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SZSE:300026' s Beneish M-Score Range Over the Past 10 Years
Min: -2.92   Med: -2.35   Max: -0.77
Current: -2.68

During the past 13 years, the highest Beneish M-Score of Tianjin Chase Sun Pharmaceutical Co was -0.77. The lowest was -2.92. And the median was -2.35.


Tianjin Chase Sun Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Tianjin Chase Sun Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Chase Sun Pharmaceutical Co Beneish M-Score Chart

Tianjin Chase Sun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.36 -2.22 -2.23 -2.58 -2.92

Tianjin Chase Sun Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.86 -2.92 -2.74 -2.82 -2.68

Competitive Comparison of Tianjin Chase Sun Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Chase Sun Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Chase Sun Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Chase Sun Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Tianjin Chase Sun Pharmaceutical Co's Beneish M-Score falls into.


;
;

Tianjin Chase Sun Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Tianjin Chase Sun Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1024+0.528 * 1.1225+0.404 * 1.0999+0.892 * 0.8434+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9238+4.679 * -0.077106-0.327 * 0.7389
=-2.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥2,994 Mil.
Revenue was 1444.836 + 1532.856 + 1463.378 + 1186.42 = ¥5,627 Mil.
Gross Profit was 731.993 + 836.236 + 750.154 + 581.936 = ¥2,900 Mil.
Total Current Assets was ¥6,278 Mil.
Total Assets was ¥11,372 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,171 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,534 Mil.
Total Current Liabilities was ¥1,669 Mil.
Long-Term Debt & Capital Lease Obligation was ¥644 Mil.
Net Income was 20.124 + 90.111 + 58.121 + -2.55 = ¥166 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 150.388 + 217.114 + 137.623 + 537.504 = ¥1,043 Mil.
Total Receivables was ¥3,220 Mil.
Revenue was 1498.955 + 1764.414 + 1659.066 + 1749.801 = ¥6,672 Mil.
Gross Profit was 767.505 + 1009.117 + 946.91 + 1136.392 = ¥3,860 Mil.
Total Current Assets was ¥7,198 Mil.
Total Assets was ¥12,378 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,277 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,969 Mil.
Total Current Liabilities was ¥1,856 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,552 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2993.742 / 5627.49) / (3219.911 / 6672.236)
=0.531985 / 0.482583
=1.1024

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3859.924 / 6672.236) / (2900.319 / 5627.49)
=0.578505 / 0.515384
=1.1225

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6277.909 + 3170.638) / 11371.586) / (1 - (7197.878 + 3277.134) / 12378.128)
=0.169109 / 0.153748
=1.0999

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5627.49 / 6672.236
=0.8434

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 3277.134)) / (0 / (0 + 3170.638))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1534.23 / 5627.49) / (1969.034 / 6672.236)
=0.272631 / 0.295109
=0.9238

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((644.261 + 1669.22) / 11371.586) / ((1551.862 + 1856.127) / 12378.128)
=0.203444 / 0.275323
=0.7389

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(165.806 - 0 - 1042.629) / 11371.586
=-0.077106

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Tianjin Chase Sun Pharmaceutical Co has a M-score of -2.68 suggests that the company is unlikely to be a manipulator.


Tianjin Chase Sun Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Tianjin Chase Sun Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Chase Sun Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 20, Quanfa Road, Tianjin Wuqing Development Area, Tianjin, CHN, 301700
Tianjin Chase Sun Pharmaceutical Co Ltd is a high-tech medicine and health industry group. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet-based therapy.
Executives
Yao Xiao Qing Director
Chen Rui Qiang Executives
Li Chun Xu Executives
Lan Wu Jun Directors, Directors, and Executives
Zheng Dan Directors, executives
Zhang Kun Executives
Gao Guo Wei Executives
Shang Xiao Mei Securities Affairs Representative
Sun Zhang Hai Director
Wu Guang Ning Supervisors
Wang Long Executives
Liu Qiang Supervisors
Ceng Guo Zhuang Director
Su Bing Jun Directors, executives
Nie Wei Supervisors

Tianjin Chase Sun Pharmaceutical Co Headlines

No Headlines